{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:06:36Z","timestamp":1790208396045,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACG Case Rep J","ACG Case Reports Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the past few years, a better understanding of the genomic alterations in lung cancer has facilitated a targeted therapy. Lung adenocarcinomas with epidermal growth factor receptor mutations have a good response to tyrosine kinase inhibitors (TKIs). Osimertinib is a third-generation TKI approved by the Food and Drug Administration (FDA). Drug-induced liver injury is a well-known adverse effect of TKIs as a group and reported to show an autoimmune hepatitis-like picture. However, little is known about the histopathologic changes with osimertinib. We present a case of drug-induced liver injury secondary to osimertinib and discuss the histopathologic findings.<\/jats:p>","DOI":"10.14309\/crj.0000000000000011","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T16:27:56Z","timestamp":1551803276000},"page":"e00011","source":"Crossref","is-referenced-by-count":13,"title":["Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib"],"prefix":"10.14309","volume":"6","author":[{"given":"Iv\u00e1n","family":"Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Division of Anatomic and Molecular Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyali","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Division of Anatomic and Molecular Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"key":"R1-20230717","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol"},{"key":"R2-20230717","first-page":"370","article-title":"Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)","volume":"20","author":"Barr","year":"2015","journal-title":"Respiratory"},{"issue":"7","key":"R3-20230717","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The Interntional Association for the Study of Lung Cancer Consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R4-20230717","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"R5-20230717","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1753465816670498","article-title":"Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: Clinical trial evidence and experience","volume":"10","author":"Sullivan","year":"2016","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"R6-20230717","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/0284186X.2017.1404634","article-title":"A systematic review of targeted agents for non-small cell lung cancer","volume":"57","author":"Vestergaard","year":"2018","journal-title":"Acta Oncol"},{"issue":"1","key":"R7-20230717","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40291-015-0176-x","article-title":"Different EGFR gene mutations in exon 18, 19 and 21 as prognostic and predictive markers in NSCLC: A single institution analysis","volume":"20","author":"Rossi","year":"2016","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"R8-20230717","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s10637-018-0608-7","article-title":"Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: A case report","volume":"36","author":"Hirabayashi","year":"2018","journal-title":"Invest New Drugs"},{"key":"R9-20230717","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5858\/arpa.2014-0214-RA","article-title":"Durg-induced liver injury","volume":"139","author":"Fisher","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"R10-20230717","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: Rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"issue":"2","key":"R11-20230717","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations","volume":"59","author":"Kleiner","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"R12-20230717","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/cld.653","article-title":"Patterns of necrosis in liver disease","volume":"10","author":"Krishna","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"5","key":"R13-20230717","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jtho.2017.01.026","article-title":"Successful osimertinib rechallenge after Severe osimertinib-induced hepatotoxicity","volume":"12","author":"Yoshida","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["ACG Case Reports Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02075970-201902000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:37:05Z","timestamp":1786541825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02075970-201902000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.14309\/crj.0000000000000011","relation":{},"ISSN":["2326-3253"],"issn-type":[{"value":"2326-3253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}